With a Phase III trial now underway for a once-weekly, long-acting version of the antipsychotic med risperidone, Lyndra Therapeutics is eyeing a large Series D to push it through a 2025 NDA filing with the goal of taking it to market in 2026.
The biotech has closed the first tranche…
